Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) signed letter of intent to acquire a 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian for CNY 500 million on September 22, 2023. Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) agreed to acquire a 50.26% stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian for CNY 500 million on October 16, 2023. As on October 9, 2023, shareholders approved the Proposal on the Acquisition of Equity Interests in Guizhou Hanfang Pharmaceutical.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.66 CNY | +4.12% | +4.54% | -17.06% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.06% | 887M | |
+33.25% | 704B | |
+28.59% | 577B | |
-3.55% | 348B | |
+18.16% | 327B | |
+4.36% | 288B | |
+14.81% | 234B | |
+4.93% | 198B | |
-9.78% | 194B | |
-3.69% | 147B |
- Stock Market
- Equities
- 603439 Stock
- News GuiZhou SanLi Pharmaceutical Co.,Ltd
- Guizhou Sanli Pharmaceutical Co.,Ltd agreed to acquire a stake in Guizhou Hanfang Pharmaceutical Co., Ltd. from Gui'an New District Shunqi Commercial Operation Management Center (Limited Partnership) and Sheng Yongjian